We offer preclinical studies using an APP/PS1 mouse model of Alzheimer’s Disease. This transgenic model features progressive, age-dependent, beta-amyloid (Aβ) pathology. These APP/PS1 mice are often used as a model for Alzheimer’s disease, including cerebral amyloid angiopathy (CAA).

Our APP/PS1 transgenic mouse model of Alzheimer’s Disease features amyloid-β plaques, microgliosis, and astrogliosis (in both brain and spinal cord). The β-amyloid pathology progresses rapidly and predictably, including extracellular, intracellular, and vascular amyloid (as shown below).  

This rodent model is used in preclinical efficacy assessments of therapeutics related to

• β-amyloid pathology
• Neuroprotection
• Neuroinflammation

At Biospective, we offer preclinical studies with our validated and readily available in-house models, as well as with commercially-available and sponsor-provided models. Our end-to-end preclinical studies include breeding, housing, dosing, in vivo imaging (MRI & PET), behavior and functional assessments, and immunohistochemistry (IHC). We specialize in high-sensitivity, quantitative immunohistochemistry image analysis.